WO2025100427A1 - 肺高血圧症の予防および/または治療用医薬 - Google Patents

肺高血圧症の予防および/または治療用医薬 Download PDF

Info

Publication number
WO2025100427A1
WO2025100427A1 PCT/JP2024/039369 JP2024039369W WO2025100427A1 WO 2025100427 A1 WO2025100427 A1 WO 2025100427A1 JP 2024039369 W JP2024039369 W JP 2024039369W WO 2025100427 A1 WO2025100427 A1 WO 2025100427A1
Authority
WO
WIPO (PCT)
Prior art keywords
aptamer
pulmonary hypertension
administration
group
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/JP2024/039369
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
良和 中岡
薫克 稲垣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Cerebral and Cardiovascular Center
Original Assignee
National Cerebral and Cardiovascular Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Cerebral and Cardiovascular Center filed Critical National Cerebral and Cardiovascular Center
Priority to JP2025556409A priority Critical patent/JPWO2025100427A1/ja
Publication of WO2025100427A1 publication Critical patent/WO2025100427A1/ja
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers

Definitions

  • the present invention relates to a pharmaceutical agent for preventing and/or treating pulmonary hypertension.
  • Pulmonary hypertension is an intractable disease with a poor prognosis that causes vascular remodeling (stenosis and obstruction) in the pulmonary arteries, leading to increased pulmonary arterial pressure and right heart failure. Pulmonary hypertension is classified into groups 1 to 5 based on the primary site of the pathology (Non-Patent Document 1). Among these, pulmonary arterial hypertension, which occurs due to pulmonary arterial remodeling such as pulmonary arterial medial thickening and intimal proliferative lesions, and chronic thromboembolic pulmonary hypertension, which occurs due to chronic thrombus obstruction in the pulmonary artery, are designated intractable diseases by the Ministry of Health, Labor and Welfare.
  • endothelin receptor antagonists (bosentan, ambrisentan, macitentan, etc.), phosphodiesterase (PDE) 5 inhibitors (sildenafil, tadalafil, etc.), soluble guanylate cyclase (sGC) stimulators (riociguat, etc.), and prostacyclin receptor (IP receptor) agonists (epoprostenol, selexipag, beraprost, iloprost, treprostinil, etc.) are used to treat pulmonary hypertension.
  • PDE phosphodiesterase
  • sGC soluble guanylate cyclase
  • IP receptor prostacyclin receptor
  • BMPR2 signal-related genes are known to be a genetic predisposition to pulmonary hypertension, but the disease penetrance is low at approximately 20%, and inflammation and exposure to exogenous chemicals are thought to be important in the development of pulmonary hypertension.
  • the inventors have reported that the interleukin-6 (IL-6)/Th17 cell/interleukin-21 (IL-21) signal axis is important in the pathogenesis of pulmonary hypertension (Non-Patent Document 2).
  • Patent Document 1 describes that substances that inhibit signal transduction from IL-21 (e.g., anti-IL-21 antibodies) can prevent and treat pulmonary hypertension.
  • Patent Document 2 describes that aptamers that bind to IL-21 are useful for preventing and treating pulmonary hypertension.
  • the objective of the present invention is to provide a novel medical use of an aptamer that binds to IL-21. Furthermore, the objective of the present invention is to provide a preferred method of use and dosage of the aptamer that binds to IL-21 for said medical use.
  • a pharmaceutical for preventing and/or treating pulmonary hypertension which comprises as an active ingredient an aptamer that binds to interleukin-21, and is administered subcutaneously.
  • the pharmaceutical composition according to the above [1], wherein the pulmonary hypertension is pulmonary arterial hypertension.
  • a pharmaceutical for preventing and/or treating pulmonary hypertension comprising as an active ingredient an aptamer that binds to interleukin-21.
  • a method for treating pulmonary hypertension comprising administering to a patient with pulmonary hypertension an effective amount of an aptamer that binds to interleukin-21.
  • a method for treating pulmonary hypertension comprising subcutaneously administering to a patient with pulmonary hypertension an effective amount of an aptamer that binds to interleukin-21.
  • An aptamer that binds to interleukin-21 for use in the prevention and/or treatment of pulmonary hypertension by subcutaneous administration [13] Use of an aptamer that binds to interleukin-21 for producing a medicament for preventing and/or treating pulmonary hypertension. [14] Use of an aptamer that binds to interleukin-21 for the manufacture of a medicament suitable for subcutaneous administration for use in the prevention and/or treatment of pulmonary hypertension.
  • the present invention provides a pharmaceutical for preventing and/or treating pulmonary hypertension, which contains as an active ingredient an aptamer that binds to IL-21.
  • the pharmaceutical of the present invention can achieve superior therapeutic effects when administered subcutaneously compared to other administration routes.
  • FIG. 1 shows the experimental protocol of Example 1. This figure shows the results of confirming the therapeutic effect of anti-rat IL-21 aptamer in a rat model of severe pulmonary hypertension.
  • RVSP right ventricular systolic pressure
  • B is right ventricle/left ventricle + septum weight ratio (RV/LV+S)
  • C is Elastica van Gieson stained image of the pulmonary artery (EVG)
  • D is vascular occlusion rate
  • E is the percentage of occluded blood vessels.
  • FIG. 2 shows the experimental protocol of Example 2.
  • FIG 1 shows the results of measuring right ventricular systolic pressure (RVSP) in a rat model of severe pulmonary hypertension after administering anti-rat IL-21 aptamer via different administration routes.
  • RVSP right ventricular systolic pressure
  • A shows the results after intraperitoneal administration
  • B shows the results after subcutaneous administration
  • C shows the results after intravenous administration
  • D shows the results after intratracheal administration.
  • Figure 1 shows the results of administering anti-rat IL-21 aptamer via different routes to a rat model of severe pulmonary hypertension and measuring the right ventricle/left ventricle + septum weight ratio (RV/LV+S).
  • FIG. 1 shows the results after calculating the vascular occlusion rate when anti-rat IL-21 aptamer was administered via different routes to a rat model of severe pulmonary hypertension.
  • A shows the results after intraperitoneal administration, (B) after subcutaneous administration, (C) after intravenous administration, and (D) after intratracheal administration.
  • FIG. 1 shows the results of measuring anti-rat IL-21 aptamer concentrations in plasma and the right upper lobe of the lung.
  • FIG. 1 shows the experimental protocol of Example 3.
  • FIG. 1 shows the experimental protocol of Example 4.
  • FIG. 1 shows the results of confirming the therapeutic effect of a rat model of severe pulmonary hypertension by combining an anti-rat IL-21 aptamer with an endothelin receptor antagonist (ERA), in which (A) is right ventricular systolic pressure (RVSP), (B) is right ventricle/left ventricle + septum weight ratio (RV/LV+S), (C) is an Elastica van Gieson stained image of the pulmonary artery (EVG), (D) is the vascular occlusion rate, and (E) is the percentage of occluded blood vessels.
  • RVSP right ventricular systolic pressure
  • RV/LV+S septum weight ratio
  • EVG Elastica van Gieson stained image of the pulmonary artery
  • E is the vascular occlusion rate
  • E is the percentage of occluded blood vessels.
  • FIG. 1 shows the experimental protocol of Example 5.
  • FIG. 1 shows the results of confirming the therapeutic effect of a rat model of severe pulmonary hypertension by combining an anti-rat IL-21 aptamer with a soluble guanylate cyclase (sGC) stimulator.
  • RVSP right ventricular systolic pressure
  • B is right ventricle/left ventricle + septum weight ratio
  • C is an Elastica van Gieson stained image of the pulmonary artery (EVG)
  • EVG is the vascular occlusion rate
  • E is the percentage of occluded blood vessels.
  • FIG. 1 shows the experimental protocol of Example 6.
  • FIG. 1 shows the results of confirming the therapeutic effect of a rat model of severe pulmonary hypertension by combining an anti-rat IL-21 aptamer with a prostacyclin receptor (IP receptor) agonist.
  • RVSP right ventricular systolic pressure
  • B is right ventricle/left ventricle + septum weight ratio
  • C is an Elastica van Gieson stained image of the pulmonary artery (EVG)
  • D is the vascular occlusion rate
  • E is the percentage of occluded blood vessels.
  • the present invention provides a pharmaceutical for preventing and/or treating pulmonary hypertension, which contains as an active ingredient an aptamer that binds to IL-21 (hereinafter referred to as the "pharmaceutical of the present invention").
  • the pharmaceutical of the present invention is preferably administered subcutaneously.
  • the aptamer that binds to IL-21 which is the active ingredient of the pharmaceutical of the present invention (hereinafter referred to as "anti-IL-21 aptamer”), is not particularly limited as long as it has activity of binding to human IL-21 and inhibiting the function of human IL-21.
  • an aptamer that has been confirmed in the above Patent Document 2 (WO2021/256530 A1) to bind to human IL-21 and inhibit the activity of human IL-21 in a cell evaluation system can be preferably used.
  • the anti-IL-21 aptamer which is an active ingredient of the pharmaceutical of the present invention, may be an aptamer comprising the base sequence shown in SEQ ID NO: 1 to 29.
  • the base sequences shown in SEQ ID NO: 1 to 29 are shown below.
  • the underlined sequences indicate consensus sequences.
  • SEQ ID NO: 21 GGA CCUUC AUCACG CGAUUACU CGUGAAU GCCCG UCC SEQ ID NO: 22: GGA CCGCC AACAAA CGAUUACU UUUGAUU GUCCG UCC SEQ ID NO: 23: GGA CCUUC AACCCG CGGCUACU CGGGAUU GCCCG UCC SEQ ID NO: 24: GA CCUUC AACCCG CGGCUACU CGGGAUU GCCCG UC SEQ ID NO: 25: GGA CCGUC AACACG CGACUACU CGUGAUU GCCCG UCC SEQ ID NO: 26: GGA CCUCC AACACG CGACUACU CGUGAUU GCCCG UCC SEQ ID NO: 27: GGA CCUUC AACACG CGACGACU CGUGAUU GCCCG UCC SEQ ID NO: 28: GGA CCUUC AACACG CGACUACC CGUGAUU GCCCG UCC SEQ ID NO: 29: GGA CCUUC AACACG CG
  • the anti-IL-21 aptamer which is the active ingredient of the pharmaceutical of the present invention, may be an aptamer that contains the base sequence shown in SEQ ID NOs: 1 to 29 above, and that contains a base sequence in which one or several nucleotides have been substituted, deleted, inserted or added, and that binds to human IL-21 and inhibits the activity of human IL-21.
  • the number of substituted, deleted, inserted or added nucleotides is not particularly limited, and may be, for example, 5, 4, 3, 2 or 1.
  • the anti-IL-21 aptamer may be a compound consisting of multiple aptamers of one type selected from the aptamers containing the base sequences shown in SEQ ID NOs: 1 to 29, or a compound consisting of at least one of two or more types of aptamers selected from the aptamers containing the base sequences shown in SEQ ID NOs: 1 to 29.
  • Each nucleotide contained in the anti-IL-21 aptamer may be the same or different, and may be a nucleotide containing a hydroxy group at the 2'-position of ribose (i.e., a natural ribonucleotide), or a nucleotide in which the hydroxy group at the 2'-position of ribose has been replaced (modified) with any atom or group.
  • ribose i.e., a natural ribonucleotide
  • Examples of the arbitrary atom or group include a hydrogen atom, a fluorine atom, an -O-alkyl group (e.g., an -O-Me group), an -O-acyl group (e.g., an -O-CHO group), an amino group (e.g., an -NH2 group ), and the like.
  • an -O-alkyl group e.g., an -O-Me group
  • an -O-acyl group e.g., an -O-CHO group
  • an amino group e.g., an -NH2 group
  • the anti-IL-21 aptamer may have polyethylene glycol (PEG) attached to its end.
  • PEG polyethylene glycol
  • the molecular weight of the PEG is not particularly limited, and may be 1,000 to 100,000, or 30,000 to 90,000.
  • the PEG may be linear or branched into two or more chains.
  • the pharmaceutical of the present invention can be used for the prevention and/or treatment of pulmonary hypertension.
  • it can be suitably used for the prevention and/or treatment of pulmonary arterial hypertension (PAH).
  • PAH pulmonary arterial hypertension
  • the pharmaceutical of the present invention can be formulated by appropriately mixing pharma- ceutical carriers or additives according to a known method for manufacturing pharmaceutical preparations (e.g., the method described in the Japanese Pharmacopoeia, etc.).
  • Specific examples of the pharmaceutical include oral or parenteral preparations such as tablets (including sugar-coated tablets, film-coated tablets, sublingual tablets, orally disintegrating tablets, buccal tablets, etc.), pills, powders, granules, capsules (including soft capsules and microcapsules), troches, syrups, liquids, emulsions, suspensions, controlled-release preparations (e.g., immediate-release preparations, sustained-release preparations, sustained-release microcapsules, etc.), aerosols, films (e.g., orally disintegrating films, oral mucosal patch films, etc.), injections (e.g., subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections, etc.), drips, transdermal preparations,
  • the blending ratio of the carrier or additive can be appropriately set based on the range normally adopted in the pharmaceutical field.
  • the carrier or additive that can be blended, but examples include various carriers such as water, physiological saline, other aqueous solvents, and aqueous or oily bases; and various additives such as excipients, binders, pH adjusters, disintegrants, absorption enhancers, lubricants, colorants, flavorings, and fragrances.
  • Additives that can be mixed with tablets, capsules, etc. include, for example, binders such as gelatin, corn starch, tragacanth, and gum arabic, excipients such as crystalline cellulose, bulking agents such as corn starch, gelatin, and alginic acid, lubricants such as magnesium stearate, sweeteners such as sucrose, lactose, or saccharin, and flavorings such as peppermint, saffron oil, or cherry.
  • binders such as gelatin, corn starch, tragacanth, and gum arabic
  • excipients such as crystalline cellulose
  • bulking agents such as corn starch, gelatin, and alginic acid
  • lubricants such as magnesium stearate
  • sweeteners such as sucrose, lactose, or saccharin
  • flavorings such as peppermint, saffron oil, or cherry.
  • the above-mentioned materials may further contain liquid carriers such as oils and fats.
  • Sterile compositions for injection can be prepared according to normal formulation procedures (for example, dissolving or suspending the active ingredient in a solvent such as water for injection or natural vegetable oil).
  • aqueous solutions for injection for example, physiological saline, isotonic solutions containing glucose and other auxiliary drugs (for example, D-sorbitol, D-mannitol, sodium chloride, etc.), etc., are used, and may be used in combination with appropriate solubilizing agents such as alcohol (ethanol, etc.), polyalcohols (propylene glycol, polyethylene glycol, etc.), and nonionic surfactants (polysorbate 80, HCO-50, etc.).
  • the oily liquid for example, sesame oil, soybean oil, etc.
  • solubilizing agents such as benzyl benzoate, benzyl alcohol, etc.
  • buffering agents e.g., phosphate buffer, sodium acetate buffer, etc.
  • soothing agents e.g., benzalkonium chloride, procaine hydrochloride, etc.
  • stabilizers e.g., human serum albumin, polyethylene glycol, etc.
  • preservatives e.g., benzyl alcohol, phenol, etc.
  • the administration route of the medicament of the present invention is not particularly limited, but subcutaneous administration can be preferably used. It has been confirmed that the medicament of the present invention has a superior therapeutic effect when administered subcutaneously compared to administration by other routes. When administered as a medicament for subcutaneous administration, it can be administered in the form of an injection.
  • Anti-IL-21 aptamers have low toxicity to humans and other mammals (e.g., rats, mice, rabbits, sheep, pigs, cows, cats, dogs, monkeys, etc.) and can be administered safely.
  • the content of anti-IL-21 aptamer in the formulation varies depending on the dosage form, administration method, carrier, etc., but is usually 0.01 to 100% (w/w) of the total formulation, and may be 0.1 to 95% (w/w).
  • the dosage of the anti-IL-21 aptamer varies depending on the severity of the disease, the drug tolerance of the recipient, body weight, age, etc., but is usually about 0.001 to about 50 mg/kg of active ingredient per day for an adult, or may be about 0.01 to about 10 mg/kg, or may be about 0.1 to about 1 mg/kg.
  • the frequency of administration is selected from once per day to once per 28 days. The frequency of administration may be once per day to once per 21 days, once per day to once per 14 days, or once per day to once per 7 days.
  • the pharmaceutical of the present invention may be used in combination with a known pulmonary hypertension treatment drug.
  • Known pulmonary hypertension treatment drugs include endothelin receptor antagonists, phosphodiesterase (PDE) 5 inhibitors, soluble guanylate cyclase (sGC) stimulants, prostacyclin (PGI 2 ) preparations, and prostacyclin receptor (IP receptor) agonists.
  • Endothelin receptor antagonists include, for example, bosentan, ambrisentan, macitentan, and the like.
  • Phosphodiesterase 5 inhibitors include, for example, sildenafil, tadalafil, and the like.
  • Soluble guanylate cyclase stimulants include, for example, riociguat, and the like.
  • Prostacyclin preparations include, for example, epoprostenol, selexipag, beraprost, iloprost, treprostinil, and the like.
  • the medicament of the present invention and the known pulmonary hypertension therapeutic drug may be administered to a subject at the same time or at different times.
  • "administered in combination” means that the application of the medicament of the present invention and the application of the known pulmonary hypertension therapeutic drug overlap, and does not require simultaneous administration.
  • the time difference between the start of administration of the medicament of the present invention and the start of administration of the known pulmonary hypertension therapeutic drug is not particularly limited, and may be 1 day or more, 2 days or more, 3 days or more, 4 days or more, 5 days or more, 6 days or more, or 7 days or more.
  • the dosage of the known pulmonary hypertension therapeutic drug may be similar to the dosage used in clinical practice, and may be appropriately selected depending on the subject, age and weight of the subject, symptoms, administration time, dosage form, administration method, combination, etc.
  • the SuHx rat model (Abe et al. Circulation 121, 2747, 2010) was used as a rat model of severe pulmonary hypertension.
  • the SuHx rat model was created as described previously. 20 mg/kg of SU5416 was subcutaneously administered to 6-week-old SD rats, and the rats were kept in a hypoxic chamber with 10% oxygen for 3 weeks, after which they were removed from the hypoxic chamber and kept under normoxic conditions for 5 weeks.
  • Anti-rat IL-21 aptamer is an aptamer that specifically inhibits the function of rat IL-21 by binding to it.
  • the anti-rat IL-21 aptamer (ILba15-6Rb-10-21-53-3'P) provided by Ribomic Co., Ltd. was used.
  • the aptamer was used after diluting to a predetermined concentration with a 5% glucose solution.
  • the sequence of the anti-rat IL-21 aptamer contains the base sequence shown in SEQ ID NO: 30 (GGAGACCUCCUCUGCCACCAAGCUGCAAGGUGGAUCCAGACGCU) provided by Ribomic Co., Ltd.
  • ILba15-6Rb-10-21-53-3'P further contains nucleotides modified with fluorine atoms or O-methyl groups, and has a structure in which polyethylene glycol (PEG) is added to the 3' end.
  • PEG polyethylene glycol
  • RVP Right ventricular pressure
  • MCT0670 pressure transducer
  • ML117 pressure amplifier
  • MAP Mean arterial pressure
  • Heart rate was calculated from the systolic peak of the arterial pressure waveform. Measurements were performed when MAP was 50 mmHg or higher and HR was 200–500 beats/min. Measurements were excluded if MAP was less than 50 mmHg or HR was less than 200 beats/min.
  • Pulmonary vascular remodeling was evaluated by the neointima area index of the vascular lumen.
  • the target vessels were pulmonary arteries in the pulmonary parenchyma, small arteries at the terminal bronchioles, and arterioles at the pulmonary lobule level, with diameters of 30-100 ⁇ m. More than 40 vessels were selected from each treatment group for evaluation. The diameter of the middle pulmonary artery was determined using an Aperio ImageScope (Leica).
  • the neointimal area index of the vascular lumen was classified into those without neointimal lesions (Open), those with intimal lesions in less than 50% of the vascular lumen (Partial closed), and those with intimal lesions occupying more than 50% of the vascular lumen (Closed), and the proportion of vessels in each group was evaluated.
  • Example 1 Therapeutic effect of anti-rat IL-21 aptamer in a rat model of severe pulmonary hypertension
  • the experimental protocol is shown in Figure 1.
  • the anti-rat IL-21 aptamer was intraperitoneally administered (1 mg/kg/3day) to the SuHx rat model once every 3 days for 3 weeks, starting 5 weeks (5w) after SU5416 administration (0w).
  • the vehicle group the vehicle (5% glucose solution) was intraperitoneally administered to the SuHx rat model once every 3 days for 3 weeks, starting 5w.
  • rats kept under normal oxygen conditions for the entire period were intraperitoneally administered 5% glucose solution once every 3 days for 3 weeks, starting 5w.
  • Right ventricular systolic pressure was measured 8 weeks after the start of the experiment (8w), and the rats were euthanized, the hearts and lungs were excised, and the tissue weights were measured and subjected to tissue analysis.
  • Example 2 Therapeutic effect of anti-rat IL-21 aptamer on severe pulmonary hypertension rat model by administration route
  • the experimental protocol is shown in Figure 3.
  • the anti-rat IL-21 aptamer was administered to the SuHx rat model once every 3 days for 5 weeks from 3 weeks (3w) after SU5416 administration (0w).
  • the vehicle group the vehicle (5% glucose solution) was administered to the SuHx rat model once every 3 days for 5 weeks from 3w.
  • rats kept under normal oxygen conditions for the entire period were administered 5% glucose solution once every 3 days for 5 weeks from 3w.
  • the administration routes were intraperitoneal (ip), subcutaneous (sc), intravenous (iv), and intratracheal (it).
  • the control group was administered only intraperitoneally. Eight weeks after the start of the experiment (8w), the right ventricular systolic pressure was measured, and after blood sampling, the rats were euthanized, the hearts and lungs were excised, and the tissue weights were measured and subjected to tissue analysis. In addition, plasma and a portion of the right upper lung lobe were used to measure the aptamer concentration. The blood and lung tissue samples were taken two days after the final administration.
  • RVSP right ventricular systolic pressure
  • Example 3 Dose-response study of subcutaneous administration of anti-rat IL-21 aptamer The experimental protocol is shown in Figure 8.
  • the anti-rat IL-21 aptamer was administered to the SuHx rat model once every three days for five weeks, starting three weeks (3w) after SU5416 administration (0w).
  • the doses were 0.1 ⁇ g/kg, 1 ⁇ g/kg, 10 ⁇ g/kg, 100 ⁇ g/kg, and 1000 ⁇ g/kg.
  • the vehicle 5% glucose solution was administered to the SuHx rat model once every three days for five weeks, starting 3w.
  • rats kept under normal oxygen conditions for the entire period were administered a 5% glucose solution once every three days for five weeks, starting 3w.
  • Right ventricular systolic pressure was measured eight weeks after the start of the experiment (8w), and the rats were euthanized, the hearts and lungs were excised, and the tissue weights were measured and subjected to tissue analysis.
  • FIG. 9 shows right ventricular systolic pressure (RVSP)
  • RVSP right ventricular systolic pressure
  • B shows right ventricle/left ventricle + septum weight ratio (RV/LV+S)
  • C shows vascular occlusion rate
  • D shows the percentage of occluded blood vessels.
  • the aptamer group significantly suppressed the increase in right ventricular systolic pressure (RVSP) at doses of 10 ⁇ g/kg/3day and 1000 ⁇ g/kg/3day.
  • RVSP right ventricular systolic pressure
  • the aptamer group also significantly reduced the vascular occlusion rate at doses of 10 ⁇ g/kg/3day and 1000 ⁇ g/kg/3day.
  • Example 4 Therapeutic effect of a combination of anti-rat IL-21 aptamer and endothelin receptor antagonist (ERA) in a rat model of severe pulmonary hypertension
  • ERA endothelin receptor antagonist
  • the experimental protocol is shown in Figure 10.
  • Macitentan MedChemExpress
  • Five groups were established: anti-rat IL-21 aptamer administration group, ERA administration group, combination administration group, solvent group, and control group.
  • SU5416 was administered to the SuHx rat model for three weeks starting five weeks (5w) after administration (0w).
  • the anti-rat IL-21 aptamer administration group and combination administration group were subcutaneously administered with anti-rat IL-21 aptamer (1mg/kg) once every three days, and the ERA administration group and solvent group were subcutaneously administered with 5% glucose solution once every three days.
  • the ERA administration group and combination administration group were administered with ERA mixed food, and the anti-rat IL-21 aptamer administration group and solvent group were given powdered standard rat food. Food was freely available using Roden cafe (Oriental Yeast) in the feeder.
  • the daily dose of ERA calculated based on food intake was approximately 30 mg/kg/day.
  • the control group consisted of rats that were kept under normal oxygen conditions throughout the experiment. Right ventricular systolic pressure was measured 8 weeks after the start of the experiment (8w), and the rats were euthanized, and the hearts and lungs were excised, tissue weights were measured, and the tissues were subjected to histological analysis.
  • Example 5 Therapeutic effect of a combination of an anti-rat IL-21 aptamer and a soluble guanylate cyclase (sGC) stimulator in a rat model of severe pulmonary hypertension
  • the experimental protocol is shown in Figure 12.
  • BAY41-2272 (Selleck) was used as the sGC stimulant.
  • Five groups were established: anti-rat IL-21 aptamer administration group, sGC stimulant administration group, combination administration group, solvent group, and control group.
  • SU5416 was administered to the SuHx rat model for three weeks starting five weeks (5w) after administration (0w).
  • the anti-rat IL-21 aptamer administration group and combination administration group were subcutaneously administered with the anti-rat IL-21 aptamer (1mg/kg) once every three days, and the ERA administration group and solvent group were subcutaneously administered with a 5% glucose solution once every three days.
  • the sGC administration group and combination administration group were administered with the sGC stimulant mixed in the feed, and the anti-rat IL-21 aptamer administration group and solvent group were given powdered standard rat feed.
  • the feed was freely available using Roden cafe (Oriental Yeast) in the feeder.
  • the daily dose of sGC stimulant was calculated based on food intake and was approximately 10 mg/kg/day.
  • the control group consisted of rats that were kept under normal oxygen conditions throughout the experiment. Right ventricular systolic pressure was measured 8 weeks after the start of the experiment (8w), and the rats were euthanized, and the hearts and lungs were excised, and the tissue weights were measured and subjected to tissue analysis.
  • Example 6 Therapeutic effect of a combination of an anti-rat IL-21 aptamer and a prostacyclin receptor (IP receptor) agonist in a rat model of severe pulmonary hypertension
  • the experimental protocol is shown in Figure 14.
  • Selexipag MedChemExpress
  • Five groups were established: anti-rat IL-21 aptamer administration group, IP receptor agonist administration group, combination administration group, solvent group, and control group.
  • SU5416 was administered to the SuHx rat model for three weeks starting five weeks after administration (5w).
  • the anti-rat IL-21 aptamer administration group and combination administration group were subcutaneously administered with the anti-rat IL-21 aptamer (1mg/kg) once every three days, and the IP receptor agonist administration group and solvent group were subcutaneously administered with 5% glucose solution once every three days for three weeks starting from 5w.
  • the IP receptor agonist administration group and combination administration group were administered with the IP receptor agonist mixed in the feed, and the anti-rat IL-21 aptamer administration group and solvent group were given powdered standard rat feed.
  • the feed was freely available using Roden cafe (Oriental Yeast) in the feeder.
  • the daily dose of sGC stimulant was calculated based on food intake and was approximately 30 mg/kg/day.
  • the control group consisted of rats that were kept under normal oxygen conditions throughout the experiment. Right ventricular systolic pressure was measured 8 weeks after the start of the experiment (8w), and the rats were euthanized, and the hearts and lungs were excised, and the tissue weights were measured and subjected to tissue analysis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/JP2024/039369 2023-11-06 2024-11-06 肺高血圧症の予防および/または治療用医薬 Pending WO2025100427A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025556409A JPWO2025100427A1 (cg-RX-API-DMAC7.html) 2023-11-06 2024-11-06

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023-189333 2023-11-06
JP2023189333 2023-11-06

Publications (1)

Publication Number Publication Date
WO2025100427A1 true WO2025100427A1 (ja) 2025-05-15

Family

ID=95695870

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2024/039369 Pending WO2025100427A1 (ja) 2023-11-06 2024-11-06 肺高血圧症の予防および/または治療用医薬

Country Status (2)

Country Link
JP (1) JPWO2025100427A1 (cg-RX-API-DMAC7.html)
WO (1) WO2025100427A1 (cg-RX-API-DMAC7.html)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021256530A1 (ja) * 2020-06-17 2021-12-23 株式会社リボミック Il-21に対するアプタマーおよびその使用
JP2022543191A (ja) * 2019-07-30 2022-10-11 エムペグ エルエイ リミテッド ライアビリティ カンパニー 増強された生理活性を有する多量体オリゴヌクレオチドの皮下送達

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022543191A (ja) * 2019-07-30 2022-10-11 エムペグ エルエイ リミテッド ライアビリティ カンパニー 増強された生理活性を有する多量体オリゴヌクレオチドの皮下送達
WO2021256530A1 (ja) * 2020-06-17 2021-12-23 株式会社リボミック Il-21に対するアプタマーおよびその使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FUKUDA, H.: "Guidelines for Treatment of Pulmonary Hypertension(JCS 2017/JPCPHS 2017)", GUIDELINES FOR TREATMENT OF PULMONARY HYPERTENSION(JCS 2017/JPCPHS 2017), THE JAPANESE CIRCULATION SOCIETY, JP, JP, pages 1 - 114, XP009563557, Retrieved from the Internet <URL:https://plaza.umin.ac.jp/~jscvs/wordpress/wp-content/uploads/2020/06/JCS2017_fukuda_h.pdfhttp://www.j-circ.or.jp/guideline/pdf/JCS2017_fukuda_h.pdf> *
MOCHIZUKI AKINORI: "Oligonucleotide aptamers: therapeutics and clinical applications", JAPANESE JOURNAL OF THROMBOSIS AND HEMOSTASIS, NIHON KESSEN SHIKETSU GAKKAI , TOKYO, JP, vol. 31, no. 1, 1 January 2020 (2020-01-01), JP , pages 66 - 70, XP093314049, ISSN: 0915-7441, DOI: 10.2491/jjsth.31.66 *

Also Published As

Publication number Publication date
JPWO2025100427A1 (cg-RX-API-DMAC7.html) 2025-05-15

Similar Documents

Publication Publication Date Title
JP6955443B2 (ja) 肺動脈性肺高血圧症の処置に関する方法および組成物
CA2458798C (en) Method for reducing hypertension and heart failure
CN110475554B (zh) 用于预防或治疗靶向鞘氨醇1-磷酸受体4的非酒精性脂肪性肝炎的组合物
AU2007220047B2 (en) Inhibition of JAK2 as a treatment of pulmonary arterial hypertension
US20120128697A1 (en) NOTCH Inhibition in the Treatment or Prevention of Atherosclerosis
JP7711962B2 (ja) 抗がん効果増進のためのERRγ抑制剤を有効成分として含む組成物の用途
MX2011003328A (es) Metodos para tratar inflamacion.
CN104011069A (zh) 心力衰竭及相关病症的治疗
RU2450824C2 (ru) Применение антагонистов il-1 для лечения подагры
US11446376B2 (en) Methods for treating heart failure using glucagon receptor antagonistic antibodies
KR20240013820A (ko) 당뇨병성 신장병을 위한 예방 및/또는 치료 약물
US20040259889A1 (en) Methods of treating pulmonary disease
AU2002341618A1 (en) Methods of treating pulmonary disease
US9457013B2 (en) Method for treating a neurological disorder associated with hypoxia using a small moleucule MIF inhibitor
JP6198742B2 (ja) 肺高血圧症
Zhang et al. Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl4-induced cirrhotic rats
JP3538616B2 (ja) 間質性肺炎治療薬および当該疾病の動物モデルの作成方法並びにそれを用いるスクリーニング方法
JP2018521077A (ja) 糖尿病性腎症を治療するためのpde4阻害剤
KR20160062517A (ko) Dpp­4 저해제를 유효성분으로 함유하는 혈관 석회화 억제용 약학적 조성물
KR20190091621A (ko) 벤조[d]싸이아졸 유도체 또는 이의 염을 유효성분으로 포함하는 면역세포 이동 관련 질환의 예방 또는 치료용 약학적 조성물
JP3306571B2 (ja) エンドセリン変換酵素阻害剤
JPWO2005046724A1 (ja) 血管障害や高血圧症の治療・予防剤、及びそのスクリーニング方法
US9238040B2 (en) Chemoprevention of colorectal cancer by mesalamine/sulfasalazine
WO2014065370A1 (ja) 肺高血圧症治療剤
JP2009511510A (ja) 肝不全の予防・治療用薬品の調製における効果の長いヒト組換え可溶性腫瘍壊死因子α受容体の使用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24888722

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2025556409

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE